Timothy J. LaBua
Overview
Tim LaBua is an experienced counselor to life science companies and venture capital firms in connection with a variety of financing and strategic partnership challenges, as well as merger and acquisition transactions.
He also has extensive experience representing publicly traded companies and helping business development teams navigate the complexities of early-stage strategic investments, purchase options, and research and development collaborations.
Career & Education
- Associate Attorney, AmLaw 50 firm
- Investment & Operations Counsel, Highfields Capital Management, LP
- Associate Attorney, AmLaw 50 firm
- Brown University, B.A.
- University of Michigan Law School, J.D., Dean's Scholarship
- Massachusetts
Timothy's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Representative Matters
Before joining Crowell Life Sciences in 2025, Tim was Principal at Faber Daeufer & Itrato PC, where he handled the following recent representative matters:
- GV (Google Ventures) in its
- Purchase of preferred equity in PeopleOne Health, Inc.
- Purchase of preferred equity in Hyperfine Research, Inc.
- Purchase of preferred equity in Adagio Therapeutics, Inc.
- Purchase of Series A-2 Preferred Stock in Verve Therapeutics, Inc.
- Purchase of preferred equity in Verve Therapeutics, Inc.
- GV and deal partners in in the purchase of preferred equity in Chroma Medicine, Inc.
- Various biotechnology companies in purchases of preferred equity
- Various biotechnology companies in asset sales
- Biotechnology company in its SAFE Financing
- Pharmaceutical company in its out-license of IP and sale of assets to a therapeutics company
- Therapeutics company its equity/debt financing and research funding from a foundation trust
- RightBrain Bio, Inc. in its SAFE Financing
- Novo Nordisk in its acquisition of gene editing assets from 2Seventy Bio, Inc. and the termination of their Hemophilia A collaboration
- ARCH in its:
- Purchase of preferred equity in Myeloid Therapeutics, Inc.
- Purchase of preferred equity in Ultivue, Inc.
- SURGE Therapeutics, Inc. in its Series B Financing
- AllerFund Ventures in numerous purchases of preferred equity
- Kanyos Bio, Inc. in its acquisition by Anokion SA
- Venture capital client in sale of certain royalty rights
- Biotechnology company in its acquisition by pharmaceutical company
- Alnylam Pharmaceuticals, Inc. in its strategic collaboration with Vir Biotechnology to develop RNAi therapeutics for infectious diseases
- Therapeutics company in its exclusive option arrangement with pharmaceutical company
Timothy's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Timothy's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
